Concepedia

Robert C. Kane

RC

Statistics

Publications

26

Citations

3.3K

H-Index

22

Active since

1975

Affiliations

Center for Drug Evaluation and Research(Current)

United States Food and Drug Administration

Harvard University

Acumen (United States)

Geisinger Medical Center

Robert C. Kane is an author at Center for Drug Evaluation and Research specializing in medicine, oncology, and pharmacology.

Publications per year

1975–2019

26

Publications

26

FDA Approval: Blinatumomab

Donna Przepiorka, Chia‐Wen Ko, Albert Deisseroth et al. · Clinical Cancer Research · 2015 · 364 citations

Medicine, Hematology, Oncology +17

United States Food and Drug Administration Approval Summary: Bortezomib for the Treatment of Progressive Multiple Myeloma after One Prior Therapy

Robert C. Kane, Ann T. Farrell, Rajeshwari Sridhara et al. · Clinical Cancer Research · 2006 · 345 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Approval Summary for Bortezomib for Injection in the Treatment of Multiple Myeloma

Peter Bross, Robert C. Kane, Ann T. Farrell et al. · Clinical Cancer Research · 2004 · 340 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Bortezomib for the Treatment of Mantle Cell Lymphoma

Robert C. Kane, Ramzi Dagher, Ann T. Farrell et al. · Clinical Cancer Research · 2007 · 333 citations · Full text

Medicine, Hematology, Pharmacotherapy +15

Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio

Kyongsun Pak, Hajime Uno, Dae Hyun Kim et al. · JAMA Oncology · 2017 · 264 citations · Full text

Public Health, Biostatistics, Oncology +15

1–5 of 26